Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · BHARAT IMMUNOLOGICALS & BIOLOG · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
BHARAT IMMUNOLOGICALS & BIOLOG is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY19–FY19 (all audited; no estimate years)
₹ crore · standalone
FY19
Revenue
84
EBITDA (ex other income)
(9)
margin %
(10.7)
Owners' profit
(6)
EPS, as reported (₹)
(1.29)
ROE % · ROCE %
(19.1) · (19.9)
Debt / equity (x)
0.00
Cash from operations
—
Capex
—
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BHARAT IMMUNOLOGICALS & BIOLOG · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
₹ crore
Q1 FY21
Q2 FY21
Q3 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q2 FY23
Q3 FY23
Revenue
19
25
25
14
25
17
26
0
Profit before tax
(1)
(6)
(2)
0
(5)
(1)
(4)
(6)
Net profit
(1)
(4)
(2)
2
(9)
(1)
(3)
(5)
EPS (₹)
(0.18)
(0.90)
(0.44)
0.45
(2.17)
(0.08)
(0.71)
(1.08)
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY19
Segment
Revenue, ₹ crore
Share %
ORAL POLIO VACCINE
84
99.9
ZINC DISPERSIBLE TABLETS
0
0.0
BIB SWEETS TABLETS
0
0.0
ZINC DISPERSIBLE TABLET
0
0.1
Total, before eliminations
84
100.0
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,21,677
34.9
5.03
22.6
13.7
17.5
11.8
32.3
DIVI S LABORATORIES LTD
2,53,976
87.0
15.15
65.5
15.3
18.8
8.7
42.8
TORRENT PHARMACEUTICALS L
1,54,957
73.1
8.81
38.5
12.2
8.0
11.8
33.1
LAURUS LABS LIMITED
1,17,877
107.7
21.70
65.6
16.4
17.2
7.2
32.0
ZYDUS LIFESCIENCES LTD
1,17,315
26.2
3.97
15.1
17.3
18.0
12.4
25.2
DR. REDDY S LABORATORIES
1,11,506
34.5
2.92
14.9
10.9
13.0
12.1
15.0
CIPLA LTD
1,10,320
32.7
3.20
16.9
11.2
14.7
8.0
19.7
MANKIND PHARMA LIMITED
1,02,829
50.3
6.21
28.3
11.7
10.8
—
27.3
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/B
0.4
3.1
7 of 163
96%
ROCE
(9.9)
10.8
169 of 183
8%
ROE
(8.3)
9.8
153 of 166
8%
Debt / Equity
0.8
0.2
151 of 166
9%
Revenue growth
(100.0)
16.3
157 of 161
0%
Profit growth
(343.1)
30.9
153 of 158
3%
Market cap
38
806
153 of 181
16%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BHARAT IMMUNOLOGICALS & BIOLOG · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
30 Sept 2026 · BSE seeks clarification on significant price movement
regulatory legal
high
—
—
17 Sept 2026 · Government approves closure of BIBCOL
regulatory legal
critical
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
